ClinicalTrials.gg
Active, not recruitingNCT06007976Updated Nov 2, 2026

LLLT to Reduce Low Back Pain

An interventional study of Erchonia® Trident in Low Back Pain, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Low Back Pain by Mayo Clinic — 2 open to participants now, 4 under way, none of them phase 3. Low Back Pain · Mayo Clinic.

Planned enrollment
3rd of 10
60 · median 39
Started
2024
the only one that year
No phase
8 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Low Back Pain by Mayo Clinic, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 8 with no phase, and was the 8th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

2 of the 10 studies in Low Back Pain by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Low Back Pain by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research study is to gather information on the effectiveness of the Trident low-level laser therapy (LLLT) in combination with clinical patient education manuals to reduce lower back pain.

Read the detailed description

Patients will be administered one of 4 treatment options using the Trident LLLT. The treatment options include 2 treatments, 4 treatments, 6 treatments or 8 treatments. All patients will receive two self-help patient education manuals. Low Back Pain will be compared among all 4 options at the end of week 6.

03

Conditions studied

  • Low Back Pain

Keywords

  • laser
  • LLLT
  • back pain
  • pain
  • low back pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reporting a primary pain point in lower back.
  • Pain intensity reported at baseline must be 4 and above on the Visual Analogue scale (PROMIS Numeric Rating Scale).
  • Individual able to participate fully in all aspects of the study and have understood and signed study .

Exclusion criteria

Exclusion Criteria:

  • Have used pain medications or participated in a pain treatment within three days of study enrollment.
  • Have an implanted device (including lap band) in the targeted area of Low Level Laser Treatment.
  • Have used an drug within 30 days of study enrollment.
  • Reports being currently pregnant, lactating, or are of or are likely to become pregnant during the low level laser treatment phase and are unwilling to use a reliable form of . Acceptable forms of contraception include: Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants; Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm); Intrauterine device (IUD); Total hysterectomy or tubal ligation; Abstinence (no sex).
  • Have a history of any major cardiovascular events including heart valve disease, ongoing angina, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, , or peripheral vascular disease.
  • Have acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, metabolic disease (such as uncontrolled diabetes type 2), active cancer, actively receiving l treatment for cancer or within 1 year of cancer remission.
  • Surgical intervention for pain within 1 month prior to enrollment.
  • Active infection, wound or other external trauma to the areas to be treated with the laser
  • Known photosensitivity disorder.
  • Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    2 treatment

    Subjects will receive 2 low-level laser therapy treatments of 20 minutes for low back pain.

    Device: Erchonia® Trident

  • Experimental
    4 treatment

    Subjects will receive 4 low-level laser therapy treatments of 20 minutes over 2 weeks for low back pain.

    Device: Erchonia® Trident

  • Experimental
    6 treatment

    Subjects will receive 6 low-level laser therapy treatments of 20 minutes over 3 weeks for low back pain.

    Device: Erchonia® Trident

  • Experimental
    8 treatment

    Subjects will receive 8 low-level laser therapy treatments of 20 minutes over 4 weeks for low back pain.

    Device: Erchonia® Trident

Interventions

  • DeviceErchonia® Trident

    Low-level laser therapy

06

What researchers measure

Primary outcomes

  1. Change in Brief Pain Inventory score

    The PROMIS Numeric Rating Scale v1.0 - Pain Intensity 1a will be used to measure pain intensity on a VAS scale where '0' is no pain and '10' being the worst imaginable pain.

    Time frame: Baseline, Week 6

  2. Change in Brief Pain Inventory score

    The PROMIS Numeric Rating Scale v1.0 - Pain Intensity 1a will be used to measure pain intensity on a VAS scale where '0' is no pain and '10' being the worst imaginable pain.

    Time frame: Baseline, Week 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 34 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2026 → Dec 2026 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Feb 16, 2024
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Mar 2027was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 2026
Nov 2, 2026
Study completion
Dec 2026→Mar 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Sep 2026→Dec 2026
    Study completion Dec 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06007976
Lead sponsor
Mayo Clinic
Responsible party
Ivana T Croghan, PhD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 23, 2023
Start date
Feb 16, 2024
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Ivana T Croghan, PhD
principal investigator · Mayo Clinic
Ryan T Hurt, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion